This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yun, H.-J.
Right arrow Articles by Choi, E.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yun, H.-J.
Right arrow Articles by Choi, E.-C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 3071-3074, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3071-3074.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro and In Vivo Antibacterial Activities of DW286, a New Fluoronaphthyridone Antibiotic

Hee-Jeong Yun,1 Yu-Hong Min,1 Jung-A Lim,1 Jin-Wook Kang,1 So-Young Kim,1 Mi-Jeong Kim,1 Jae-Hee Jeong,1 Yun-Jeong Choi,1 Hyun-Jin Kwon,2 Yong-Ho Jung,2 Mi-Ja Shim,3 and Eung-Chil Choi1*

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742,1 Dong-Wha Pharmaceutical Ind. Co., Ltd., Anyang, Kyonggi 430-017 ,2 Department of Life Science, The University of Seoul, Seoul 130-743, Korea3

Received 3 December 2001/ Returned for modification 28 March 2002/ Accepted 26 May 2002

The in vitro and in vivo activities of DW286, a novel fluoronaphthyridone with potent antibacterial activity, were compared with those of ciprofloxacin, gemifloxacin, sparfloxacin, and trovafloxacin. Against gram-positive bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Enterococcus faecalis, the in vitro activity of DW286 was stronger than that of any other reference antibiotic. Against gram-negative bacteria, the activity of DW286 was similar to those of trovafloxacin and gemifloxacin but was weaker than that of ciprofloxacin. In a mouse systemic infection caused by three S. aureus strains, including methicillin-resistant S. aureus and quinolone-resistant S. aureus (QRSA), DW286 demonstrated the most potent activity, as found in vitro. Specially, DW286 is >=8-fold more active against QRSA than the other fluoroquinolones. And the 50% protective doses for DW286 were correspondent with the in vitro activities.

* Corresponding author. Mailing address: College of Pharmacy, Seoul National University, San 56-1, Shillim-Dong, Kwanak-Gu, Seoul 151-742, Korea, Phone: 82-2-880-7874. Fax: 82-2-886-5802. E-mail: ecchoi{at}snu.ac.kr.

Antimicrobial Agents and Chemotherapy, September 2002, p. 3071-3074, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3071-3074.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kwon, A.-R., Min, Y.-H., Ryu, J.-M., Choi, D.-R., Shim, M.-J., Choi, E.-C. (2006). In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother 58: 684-688 [Abstract] [Full Text]  
  • Kim, E.-J., Kim, K.-S., Shin, W.-H. (2005). Electrophysiological safety of DW-286a, a novel fluoroquinolone antibiotic agent. Hum Exp Toxicol 24: 19-25 [Abstract]  
  • Kim, M.-J., Yun, H.-J., Kang, J.-W., Kim, S., Kwak, J.-H., Choi, E.-C. (2003). In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother 51: 1011-1016 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»